
## Said Dermime MSc;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5041721/publications.pdf Version: 2024-02-01



SAID DEDMIME MSC.

#	Article	IF	CITATIONS
1	Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. Seminars in Cancer Biology, 2022, 83, 152-165.	4.3	37
2	Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927.		14
3	The potential role of vitamin C in empowering cancer immunotherapy. Biomedicine and Pharmacotherapy, 2022, 146, 112553.	2.5	24
4	Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540.	1.5	225
5	Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 99.	3.5	44
6	A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer. Translational Lung Cancer Research, 2022, 11, 607-616.	1.3	5
7	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. Journal of Experimental and Clinical Cancer Research, 2021, 40, 74.	3.5	19
8	Regulation of Circular RNA CircNFATC3 in Cancer Cells Alters Proliferation, Migration, and Oxidative Phosphorylation. Frontiers in Cell and Developmental Biology, 2021, 9, 595156.	1.8	19
9	In vitro Interleukin-7 treatment partially rescues MAIT cell dysfunction caused by SARS-CoV-2 infection. Scientific Reports, 2021, 11, 14090.	1.6	9
10	The expression of hACE2 receptor protein and its involvement in SARS-CoV-2 entry, pathogenesis, and its application as potential therapeutic target. Tumor Biology, 2021, 43, 177-196.	0.8	5
11	Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. Npj Vaccines, 2021, 6, 107.	2.9	12
12	The role of PAK4 in the immune system and its potential implication in cancer immunotherapy. Cellular Immunology, 2021, 367, 104408.	1.4	11
13	Anti-cancer effects of Tranilast: An update. Biomedicine and Pharmacotherapy, 2021, 141, 111844.	2.5	18
14	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	1.3	12
15	Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer. Frontiers in Immunology, 2021, 12, 781872.	2.2	3
16	Sanguinarine mediated apoptosis in Non-Small Cell Lung Cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway. Biomedicine and Pharmacotherapy, 2021, 144, 112358.	2.5	25
17	17â€Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients. , 2021, 9, A19-A19.		1
18	736â€Treatment with decitabine (DAC) induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer 2021. 9. A767-A767.		0

#	Article	IF	CITATIONS
19	Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review. Frontiers in Immunology, 2020, 11, 1354.	2.2	19
20	Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report. , 2020, 8, e001278.		9
21	Prevalence and Type Distribution of High-Risk Human Papillomavirus (HPV) in Breast Cancer: A Qatar Based Study. Cancers, 2020, 12, 1528.	1.7	19
22	Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells. Cancers, 2020, 12, 351.	1.7	30
23	Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 438.	1.8	57
24	Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. Journal of Translational Medicine, 2020, 18, 140.	1.8	59
25	Curcumin Induces Apoptotic Cell Death via Inhibition of PI3-Kinase/AKT Pathway in B-Precursor Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2019, 9, 484.	1.3	56
26	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Translational Lung Cancer Research, 2019, 8, 413-428.	1.3	95
27	The Role of Extracellular Vesicles as Modulators of the Tumor Microenvironment, Metastasis and Drug Resistance in Colorectal Cancer. Cancers, 2019, 11, 746.	1.7	42
28	Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015.	2.2	39
29	Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling. Frontiers in Oncology, 2019, 9, 285.	1.3	31
30	Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation. Scientific Reports, 2019, 9, 1554.	1.6	18
31	Greensporone A, a Fungal Secondary Metabolite Suppressed Constitutively Activated AKT via ROS Generation and Induced Apoptosis in Leukemic Cell Lines. Biomolecules, 2019, 9, 126.	1.8	13
32	Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 782-794.	0.6	29
33	RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology, 2019, 54, 1-13.	4.3	115
34	Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Annals of Translational Medicine, 2019, 7, S22-S22.	0.7	2
35	Dysregulated expression of SKP2 and its role in hematological malignancies. Leukemia and Lymphoma, 2018, 59, 1051-1063.	0.6	16
36	PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells. Annals of Oncology, 2018, 29, x14-x15.	0.6	0

#	Article	IF	CITATIONS
37	Curcumin-Mediated Degradation of S-Phase Kinase Protein 2 Induces Cytotoxic Effects in Human Papillomavirus-Positive and Negative Squamous Carcinoma Cells. Frontiers in Oncology, 2018, 8, 399.	1.3	19
38	Role of Epstein–Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target. Frontiers in Oncology, 2018, 8, 257.	1.3	32
39	Greensporone C, a Freshwater Fungal Secondary Metabolite Induces Mitochondrial-Mediated Apoptotic Cell Death in Leukemic Cell Lines. Frontiers in Pharmacology, 2018, 9, 720.	1.6	23
40	NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Frontiers in Immunology, 2018, 9, 947.	2.2	261
41	Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. Molecular Cancer, 2018, 17, 31.	7.9	79
42	Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. Frontiers in Immunology, 2018, 9, 1769.	2.2	15
43	Hematopoietic stem cell transplantation in qatar: One-year anniversary. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 299-302.	0.6	0
44	Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells. PLoS ONE, 2017, 12, e0180895.	1.1	36
45	Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges. Current Vascular Pharmacology, 2017, 15, 339-351.	0.8	143
46	MAP kinase phosphatase DUSP1 is overexpressed in obese humans and modulated by physical exercise. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E71-E83.	1.8	54
47	Physical Exercise Reduces the Expression of RANTES and Its CCR5 Receptor in the Adipose Tissue of Obese Humans. Mediators of Inflammation, 2014, 2014, 1-13.	1.4	41
48	Paraneoplastic neuromyelitis optica spectrum disorder associated with stomach carcinoid tumor. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 116-119.	0.6	29
49	Overexpression of the cancer-related DUSP1 gene in human obesity and its modulation by physical exercise. , 2014, 2, .		0
50	WT1 peptide analogue WT1-126Y enhances leukemia lysis. , 2014, 2, .		0
51	The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 1-17.	0.6	83
52	Immunohistochemical profiling of the heat shock response in obese non-diabetic subjects revealed impaired expression of heat shock proteins in the adipose tissue. Lipids in Health and Disease, 2014, 13, 106.	1.2	43
53	IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunology, 2014, 15, 19.	0.9	51
	Man Kinggo Dhaanhataaa Duan 1 Ia Quangungoo d In Llumaan Ohaas And Madulatad Du Dhusiaal Suguriaa		

<sup>54</sup> Map Kinase Phosphatase Dusp1 Is Overexpressed In Human Obese And Modulated By Physical Exercise. , 2014, , .

#	Article	IF	CITATIONS
55	Interaction of Osteopontin with IL-18 in Obese Individuals: Implications for Insulin Resistance. PLoS ONE, 2013, 8, e63944.	1.1	55
56	DNAJB3/HSP-40 Cochaperone Is Downregulated in Obese Humans and Is Restored by Physical Exercise. PLoS ONE, 2013, 8, e69217.	1.1	58
57	Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity. PLoS ONE, 2013, 8, e75342.	1.1	75
58	Cancer Diagnosis, Treatment and Therapy. Journal of Carcinogenesis & Mutagenesis, 2013, S14, .	0.3	1
59	PO42 Multiplexed analysis of inflammatory, metabolic and stress markers in obese subjects before and after a defined exercise program. Cytokine, 2012, 59, 532.	1.4	Ο
60	Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. Journal of Inflammation, 2012, 9, 48.	1.5	145
61	Association of obesity with down-regulation of heat shock protein 40 expression and evidence that exercise retrieves its normal expression. BMC Proceedings, 2012, 6, .	1.8	0
62	Therapeutic targeting of B7-H1 in breast cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 1211-1225.	1.5	36
63	Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematology/ Oncology and Stem Cell Therapy, 2010, 3, 24-33.	0.6	8
64	Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Research, 2010, 12, R48.	2.2	191
65	Enhancement of lytic activity of leukemic cells by CD8 <sup>+</sup> cytotoxic T lymphocytes generated against a WT1 peptide analogue. Leukemia and Lymphoma, 2009, 50, 260-269.	0.6	10
66	FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 2008, 8, 57.	1.1	178
67	The Wilms' Tumor Antigen Is a Novel Target for Human CD4+ Regulatory T Cells: Implications for Immunotherapy. Cancer Research, 2008, 68, 6350-6359.	0.4	41
68	Breast Carcinoma–Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes. Cancer Research, 2008, 68, 2717-2725.	0.4	129
69	Cancer Stem Cell Immunotherapy: the Right Bullet for the Right Target. Hematology/ Oncology and Stem Cell Therapy, 2008, 1, 1-2.	0.6	7
70	CD4+ Regulatory T Cells Specific for the WT1 Antigen Are Present in Acute Myeloid Leukemia Patients: Implication for Immunotherapy Blood, 2008, 112, 1933-1933.	0.6	0
71	Comment on "Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells― Journal of Immunology, 2007, 179, 732-732.	0.4	6
72	Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience. BMC Cancer, 2007, 7, 222.	1.1	76

#	Article	IF	CITATIONS
73	Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. International Journal of Cancer, 2007, 121, 751-758.	2.3	132
74	The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors. Neoplasia, 2006, 8, 190-198.	2.3	505
75	Cd8 T-cell recognition of human 5T4 oncofetal antigen. International Journal of Cancer, 2006, 119, 1638-1647.	2.3	26
76	The B7-H1 Protein is Expressed in Breast Cancer Patients: Correlation With the Clinicopathological Parameters. Journal of Immunotherapy, 2005, 28, 630-631.	1.2	0
77	Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma. Leukemia and Lymphoma, 2005, 46, 497-507.	0.6	10
78	Vaccine and antibody-directed T cell tumour immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2004, 1704, 11-35.	3.3	41
79	Use of adenoviruses encodingCD40L orIL-2 against B cell lymphoma. International Journal of Cancer, 2004, 111, 910-920.	2.3	20
80	Adoptive Transfer of Anti-idiotypic T Cells Cure Mice of Disseminated B Cell Lymphoma. Journal of Immunotherapy, 2004, 27, 227-231.	1.2	12
81	Immunization with a Recombinant Adenovirus Encoding a Lymphoma Idiotype: Induction of Tumor-Protective Immunity and Identification of an Idiotype-Specific T Cell Epitope. Journal of Immunology, 2002, 168, 3983-3991.	0.4	49
82	Cancer vaccines and immunotherapy. British Medical Bulletin, 2002, 62, 149-162.	2.7	60
83	Developing effective cancer vaccines: design and monitoring are critical. British Journal of Cancer, 2001, 84, 1433-1436.	2.9	6
84	Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Therapy, 2000, 7, 1680-1689.	2.3	39
85	GENETIC APPROACHES TO VACCINATION FOR LYMPHOMA. Biochemical Society Transactions, 1999, 27, A139-A139.	1.6	0
86	HLA Binding Characteristics and Generation of Cytotoxic Lymphocytes against Peptides Derived from Oncogenic Proteins. Tumori, 1997, 83, 847-855.	0.6	4
87	Preferential usage of T cell receptor (TCR) V β by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease. Bone Marrow Transplantation, 1997, 19, 899-903.	1.3	28
88	Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1997, 19, 989-999.	1.3	94
89	Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. British Journal of Haematology, 1996, 93, 606-612.	1.2	48
90	Interaction of natural killer cells with MHC class II: reversal of HLAâ€DR1â€mediated protection of K562 transfectant from natural killer cellâ€mediated cytolysis by brefeldinâ€A. Immunology, 1996, 87, 481-486.	2.0	32

#	Article	IF	CITATIONS
91	Acute Promyelocytic Leukaemia Cells Resistant to Retinoic Acid Show Further Perturbation of the RARα Signal Transduction System. Leukemia and Lymphoma, 1995, 16, 289-295.	0.6	21
92	The Role of the Immune System in Anti-Tumour Responses. Drugs and Aging, 1995, 7, 266-277.	1.3	4
93	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. , 0, , .		4
94	Mesenchymal Stem Cells as Immunomodulators in Transplantation. , 0, , .		0